What type of study is this?

This is a Literature Review study.

October 10, 2025Open Access

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature Review

View Full Paper

Ask AI

Bookmark

Authors

PSPetra SulićUniversity Hospital Centre Zagreb APAndrea Ražić PavičićUniversity Hospital Centre Zagreb BIBiljana Đapić IvančićUniversity Hospital Centre Zagreb

Discussion

Member takes

Implication

Literature review highlights genetic factors and biomarkers impacting treatment-resistant depression, indicating novel pathways for personalized therapy.

Key Points

Genetic factors are key contributors to treatment-resistant depression and recovery, suggesting targeted interventions.
Studies identified neuroplasticity-related genes that correlate with resistance and relapse in 30-40% of patients diagnosed with major depressive disorder.
Narrative review of literature focused on DNA- and RNA-based biomarkers through genome-wide association studies and neuroimaging analyses.
Integration of genetic and microRNA insights may enhance individualized treatment strategies and therapeutic monitoring.

Cite This Study

Sulić et al. (2025) studied this question.

synapsesocial.com/papers/68e861907ef2f04ca37e40dd https://doi.org/10.20944/preprints202509.2347.v1

View Full Paper

Ask AI

Bookmark

Implication

Literature review highlights genetic factors and biomarkers impacting treatment-resistant depression, indicating novel pathways for personalized therapy.

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider